Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2018 Oct;32(5):853-864. doi: 10.1016/j.hoc.2018.05.012. Epub 2018 Jul 19.

First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.

Author information

1
Immunology Program, Memorial Sloan Kettering Cancer Center, 408 East 69th Street, New York, NY 10021, USA.
2
Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Electronic address: Palombam@mskcc.org.

Erratum in

  • Erratum. [Hematol Oncol Clin North Am. 2019]

Abstract

Waldenström macroglobulinemia (WM) is an indolent B-cell lymphoma that is heavily dependent on Bruton tyrosine kinase (BTK) hyperactivation. Ibrutinib is a first-generation BTK inhibitor that has shown high activity and durable responses in patients with relapsed/refractory WM. Newer and more selective BTK inhibitors are currently being tested in several clinical trials and are expected to address the toxicity and the acquired resistance observed in patients receiving ibrutinib. Updates on ibrutinib and second-generation BTK inhibitors are summarized in this review.

KEYWORDS:

BTK; Ibrutinib; Second-generation BTK inhibitors; Waldenström macroglobulinemia

PMID:
30190023
DOI:
10.1016/j.hoc.2018.05.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center